fda semaglutide compounding warning november 2025 Drug compounders sue over declaration ending Wegovy shortage UPDATE: Two Considerations When Prescribing
Description
Because obesity and substance abuse are so prevalent in the United States, GLP-1RA drugs may be uniquely helpful in addressing overconsumption and addiction issues thereby improving overall health and life expectancy
The ATTAIN-1 trial , set for July 2025, is evaluating weight loss in people with obesity or overweight who have weight-related health conditions
Instead of standard dose increases, use smaller increments
Stay Hydrated Alcohol dehydrates the body, which can worsen side effects like dizziness and fatigue
Provider Detail Provider Detail on GLP-1 Compare
Dossat et al., 2011
